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Abstract A high level of lipoprotein(a) (Lp(a)) is recog-
nized as an independent and additional cardiovascular risk
factor contributing to the risk of early onset and progressive
course of cardiovascular disease (CVD). All lipid lowering
medications in use mainly lower low density lipoprotein-
cholesterol (LDL-c) with no or limited effect on levels of
Lp(a). Niacin, the only component lowering Lp(a), is firstly
often poorly tolerated and secondly not available anymore
in many countries. A level of <50 mg/dl was recommended
recently as the cut off level for clinical use and decision
making. Since lipoprotein apheresis (LA) lowers not only
LDL-c but also Lp(a) significantly, its use is recommended
in some countries in very high-risk patients with early or
progressive CVD. Retrospective analyses show that regu-
lar LA improves the course of CVD. This is supported by
a recent prospective observational trial and data of the Ger-
man Lipoprotein Apheresis Registry. Despite many treat-
ment options, all too often it is not possible to reduce LDL-
c levels to target and to reduce Lp(a) levels sustainably at
all. Therefore, new drug therapies are awaited. Some of the
lipid modifying drugs in development lower Lp(a) to some
extent in addition to LDL-c; the only specific approach is
the apoprotein(a) antisense oligonucleotide. Currently LA
is the standard of care as a last resort treatment in high-
risk patients with elevated Lp(a) and severe CVD despite
optimal control of all other cardiovascular risk factors.
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Introduction
Lipoprotein(a) (Lp(a)) in man was first described in 1963 by
Berg, who stated that the level of Lp(a) is mainly inherited
and that high levels of Lp(a) are associated with premature
atherosclerosis [1]. This has been confirmed thereafter by
observational data and supported in recent years by genetic
data establishing Lp(a) as a causal factor for the develop-
ment of atherosclerosis [2–8]. The European Guidelines on
vascular disease prevention in clinical practice [9] mention
high levels of Lp(a) as being associated with an increased
risk of CVD and suggest to use levels of Lp(a) for risk
stratification in individuals at moderate risk or with a pos-
itive family history of early CVD. The consensus paper
of the European Atherosclerosis Society (EAS) [10] offers
guidance. Lp(a) should be measured e. g. in all individuals
at intermediate or high risk of CVD, in case of premature
CVD, familial hypercholesterolaemia, premature CVD or
high Lp(a) in the family, progressive CVD despite statin
therapy.
Lp(a) consists of a low density lipoprotein (LDL) parti-
cle and an additional protein called apoprotein(a) (apo(a)),
linked to apoprotein B (apoB) 100 of the LDL particle via
one disulfide bond. Mostly the level depends on the size of
apo(a) [11] and both are negatively correlated. The different
laboratory methods are not comparable and results cannot
be converted. If comparing data the used methods have to
be taken into account. The consensus statement of the EAS
recommended the use of an isoform insensitive assay and
suggested a level of <50 mg/dl as desirable [10]. Since risk
K
Hyperlipoproteinaemia(a) – apheresis and emerging therapies 13
increases with increasing levels of Lp(a) and interventional
data are missing, there is no established threshold.
Established therapies
Drugs
Some data show either a decrease or an increase of Lp(a)
by statins [12], but mostly Lp(a) is not affected by statins
[10, 13, 14] nor by ezetimibe [15]. Nicotinic acid (niacin)
reduces Lp(a) besides positive effects on LDL-c, high den-
sity lipoprotein-cholesterol (HDL-c), and triglycerides [16];
high doses (2–4 g) reduce Lp(a) significantly [17]. Whether
this holds true for individuals with high levels of Lp(a) has
never been shown. A meta-analysis of the beneficial effects
of nicotinic acid on cardiovascular events [18] did not dis-
criminate whether the lowered levels of Lp(a) might have
contributed to the positive results or not. It has to be men-
tioned that these data are mainly from the pre-statin era
and would have to be confirmed in cohorts treated in line
with current options and guidelines. In the EAS consensus
paper niacin is recommended to reduce high levels of Lp(a)
[10]. Since 2013 niacin is not available in Europe. In sum-
mary, no established drug treatment option to reduce Lp(a)
is available at the moment.
Lipoprotein apheresis
Lipoprotein apheresis (LA) is in clinical use for over
30 years [19] and reduces apoB100 containing lipoproteins
(namely LDL-c and Lp(a)). A single treatment reduces
both by about 60–70%. The following increase is rapid
[20]. For this reason, LA has to be repeated regularly and
is done every week in most or every two weeks in some
countries. Guidelines of several countries recommend LA
in very high risk patients as a last resort therapy to lower
LDL-c in addition to maximal (tolerated) lipid lowering
medication. Few countries also consider high levels of
Lp(a) as an indication for LA in very high risk patients
[21–24].
There are no randomised prospective trials. LA has ben-
eficial effects regarding endothelial function and myocar-
dial perfusion in patients with high levels of Lp(a) [25].
Retrospective evaluations of clinical data and analyses of
the German Lipoprotein Apheresis Registry (GLAR) show
that cardiovascular events were reduced significantly after
establishing regular LA [26–28]. One retrospective evalua-
tion indicates that patients with elevated Lp(a) irrespective
of the LDL-c level have a greater benefit from LA than pa-
tients with low Lp(a) and high levels of LDL-c [29]. One
prospective open-label trial used atorvastatin plus the a se-
lective Lp(a) lowering apheresis system (treatment group)
and atorvastatin alone (control group). After 18 months
a small but significant regression of coronary atherosclero-
sis was documented by angiography in the LA group [30].
The Pro(a)-LiFe-study, a non-randomised prospective ob-
servational multicentre study in high-risk patients, showed
a reduction of major adverse cardiac events and of major
adverse non-cardiac events after two [31] as well as after
five years [32] of apheresis therapy.
Lipoprotein apheresis is well tolerated and safe in clini-
cal use [24, 33] even for 2–3 decades of treatment. Several
obstacles are opposed to a wide clinical use: it is time con-
suming, expensive, only offered in specialised centres, and
mostly not covered by insurance companies.
Emerging therapies
In recent years several new lipid modifying approaches
mostly addressing LDL-c were investigated. Inhibitors
of the cholesterol ester transfer protein (CETP) increas-
ing HDL-c and reducing LDL-c are not approved yet.
In a phase-2 trial Anazetrapib additionally lowered Lp(a)
by 50% [34]. In the REALIZE trial Anazetrapib showed
a substantial reduction of Lp(a) by 31.8% in patients with
heterozygous familial hypercholesterolaemia (FH) [35].
TA-8995, a newer agent, lowered Lp(a) in patients with
dyslipidaemia by 36.9% (5 mg) and 33.4% (10 mg) at
week 12 in a phase 2 trial [36]. The REVEAL trial using
Anacetrapib to be published in 2017 will show whether
this lipid modifying approach is beneficial in patients with
established vascular disease [37].
The apoB antisense oligonucleotide (ASO) Mipomersen
is approved in the US but not in Europe [38, 39]. Besides the
reduction of LDL-c via less hepatic production of very low
density lipoprotein (VLDL) Lp(a) is reduced by a still un-
clear mechanism. In a randomized trial Mipomersen [40] re-
duced initially elevated levels of Lp(a) significant by 31.1%.
In patients with heterozygous FH and coronary heart dis-
ease Mipomersen was added to lipid lowering therapy and
reduced Lp(a) by 21.1% [41]. Thus, Mipomersen might
reduce the necessity for lipoprotein apheresis in high-risk
patients [42].
Lomitapide, an inhibitor of the microsomal triglyceride
transfer protein (MTP), lowers LDL-c by reducing the as-
sembly of VLDL in the liver as well of chylomicrons in the
intestine. This is the only approach independent of the func-
tionality of LDL-receptors. For this reason, the MTP-in-
hibitor Lomitapide significantly lowers LDL-c in homozy-
gous FH (hoFH). Efficacy and safety in patients with hoFH
were assessed in a single-arm, open-label, phase-3 study.
Lp(a) was reduced by 19% at week 56 but at week 78 this




Like the LDL-receptor the proprotein convertase subtilisin/
kexin type 9 (PCSK9) is produced in the liver cells and
released into the circulation. If PCSK9 is attached to the
complex of LDL-receptor and LDL-c the receptor is de-
graded after internalisation and thus cannot be recycled for
further uptake of LDL-c. Loss of function mutations come
along with lower levels of LDL-c lifelong and are linked to
a lower rate of cardiovascular events [44]. Two PCSK9-in-
hibitors (fully humanized monoclonal antibodies) to mimic
these beneficial “natural” effects by binding PCSK9 and
thus hampering the intracellular lysis of the LDL-recep-
tor are approved. Overall, safety and tolerability profiles
are very promising in both of the huge trial programmes.
Long-term results show a sustained significant reduction of
LDL-c [45, 46]. The LDL-c lowering effect is dependent on
the functionality of the LDL-receptors and can vary widely.
Mean LDL-c reduction is about 50–60% and in some trials
a lowering of Lp(a) [45–48] was seen as well (Evolocumab
25.5% [46], Alirocumab 30.2% [45]).
A pooled analysis [48] of three phase-2 Alirocumab tri-
als specifically analysed the effect on Lp(a). Baseline lev-
els between 2 and 181 mg/dl were parted in two groups (
and ≥50 mg/dl). In absolute values Lp(a) was reduced by
3.5 mg/dl and 27 mg/dl (mean), respectively, or relatively
by 36% and 27% (median), respectively. In patients with
LDL-receptor negative hoFH evolocumab was, as expected,
ineffective in reducing LDL-c but all the same Lp(a) was
lowered by 20% [49]. The upregulation of other receptors,
e. g. the VLDL-receptor that mediates the uptake of Lp(a)
into macrophages, might be an explanation for this finding.
Some data show an increased catabolic fraction rate, others
a reduced synthesis [50]. The development of bococizumab
was terminated in November 2016 due to an unexpected
decline of effectivity over time, a higher level of immuno-
genicity, and more frequent injection site reactions [51].
The results of the endpoint trials are expected in early
2017 (Evolocumab [52]) and in 2018 (Alirocumab [53]).
Whether lowering Lp(a) by PCSK9-inhibitors contributes
to the expected beneficial cardiovascular effects will have
to be addressed in specifically designed trials.
Apo(a) antisense oligonucleotide
The ASO molecule IONIS-APO(a)-Rx specifically ad-
dresses the mRNA of apo(a). After a positive trial in
transgenic mice [54] a phase-1 trial in healthy volunteers
with Lp(a) levels ≥25 nmol/l was conducted. Various doses
of the ASO lowered Lp(a) significantly (no relevant re-
duction of other lipoproteins). The highest dose of 300 mg
reduced Lp(a) by 77.8%. This effect was sustained and
Lp(a) was still lowered 84 days after the last dose [55].
Data of a phase-2 trial are awaited. If effectivity and safety
are shown this ASO would for the first time allow trials to
address the question if the isolated lowering of high levels
of Lp(a) results in lesser CVD.
Conclusion
The new drug developments will enable us to reduce LDL-c
as significantly as never before with more high-risk patients
reaching their treatment goals. The results of the endpoint
trials will show to what extent this contributes to the ex-
pected reduction of cardiovascular events and deaths. The
question if the concomitant lowering effect of Lp(a) is ben-
eficial in addition has never been addressed so far. This will
have to be evaluated in trials specifically addressing patients
with high levels of Lp(a) and CVD. It is far more reason-
able to address this question with the apo(a) ASO. So far,
there are no data for any established or newly developed
agent proving that the Lp(a) lowering effect is beneficial in
high-risk cardiovascular patients.
All available data regarding lipoprotein apheresis, though
not from RCTs, at least strongly support its beneficial ef-
fect of reducing cardiovascular events. In patients with con-
trolled cardiovascular risk factors, LDL-c at goal, progres-
sive cardiovascular disease, and markedly elevated levels of
Lp(a) lipoprotein apheresis remains the only available and
optimal care. As of today, it should be considered in high-
risk patients wherever it is available.
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